Binaxnow COVID-19 Antigen Self Test, 2 Ct.

BinaxNOW COVID-19 Antigen Self Test 2-count kit Feeling sick? Act quick! Know now with BinaxNOW™ COVID-19 rapid test kit - a fast, reliable antigen test that detects COVID-19 infection. ¹ Trusted TechnologyBinaxNOW COVID-19 home test uses the same technology used by doctors to test for COVID-19. Detects multiple COVID-19 variants, including Delta...

Does Not Apply

Many In Stock

Title
-
+
$19.92

BinaxNOW COVID-19 Antigen Self Test 2-count kit 

Feeling sick? Act quick! Know now with BinaxNOW™ COVID-19 rapid test kit - a fast, reliable antigen test that detects COVID-19 infection. ¹ 

Trusted Technology

BinaxNOW COVID-19 home test uses the same technology used by doctors to test for COVID-19. Detects multiple COVID-19 variants, including Delta and Omicron*. Each Test Kit Contains: 2 Test Cards, 2 Swabs, 2 Dropper Bottles and instructions for use. ²

Fast Results

This easy-to-use COVID-19 test kit is FDA Authorized, HSA/FSA eligible and provides fast, reliable results in just 15 minutes - no prescription or lab submission required. BinaxNOW™ rapid antigen tests are suitable for kids ages 2-14 when administered by an adult and for all people 15 and older to self-administer with easy-to-follow instructions. ³

Repeat Testing

For repeat testing with at-home COVID-19 tests, symptomatic individuals should test twice over 3 days, with at least 48 hours between tests. Asymptomatic individuals should test three times over 5 days, with at least 48 hours between tests. ⁴

*Abbott conducted an analysis of the detection of multiple SARS-CoV-2 strains and predicts no impact to the performance of our BinaxNOW COVID-19 Antigen Self Test.

The BinaxNOW™ COVID-19 Antigen Self Test has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization. It has been authorized only for the detection of proteins from SARSCoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.